Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles